Clinical trials: ifosfamide
Non-Seminomatous Germ Cell Tumor
Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors
This is a prospective multicenter, non-randomized research program that includes: a phase IV study (for all patients) with a collection of tissue specimens of tumor, a phase II study (for patients with primary mediastinal tumors…
- Trial name
- VAPOR (NCT05705687)
- Testing
- BEP Protocol, Dose-dense regimen, Early tumor resection or HD-CT
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Germ Cell Tumors, Hepatic Cancer
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Life-threatening thrombocytopenia (low platelet count) and neutropenia (low white blood count) remain the major dose-limiting toxicities following chemotherapy treatment for cancer.
- Conditions
- Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00187109
- Testing
- Recombinant Human Thrombopoietin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma
Therapy for Children With Advanced Stage High Risk Neuroblastoma
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases.
- Trial name
- NCT00186849
- Testing
- Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Jude Children's Research Hospital
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrolizumab, radiation therapy and surgery to standard of care treatment…
- Conditions
- Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT07823491
- Testing
- Biospecimen Collection, Computed Tomography, Doxorubicin
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
The goal of this open, single-arm practical, phase II, clinical study is to evaluate the efficacy and safety of the mitoxantrone hydrochloride liposome injection-containing regimens in bridging therapies of CD19 CAR-T cells.
- Trial name
- NCT06220097
- Testing
- Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Solid Tumors, Advanced Cancer
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received chemotherapy.
- Trial name
- NCT00147225
- Testing
- AMG 531, Carboplatin, Adriamycin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether giving chemotherapy in addition to standard therapy is a more effective treatment for…
- Trial name
- NCT00003240
- Testing
- cisplatin, ifosfamide, mitomycin C
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
Crohn's Disease
Autologous Transplant Targeted Against Crohn's
This study is a new Phase II trial to assess the toxicity and efficacy of autologous hematopoietic stem cell transplantation (HSCT) utilizing a new non-myeloablative conditioning regimen in patients with high-risk Crohn's disease…
- Trial name
- ATTAC (NCT04154735)
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma, Extranodal NK-T-Cell
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.
- Trial name
- NCT03154918
- Testing
- GLIDE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan University
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not…
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma
- Trial name
- NCT04684368
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- Children's Oncology Group
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT01172912
- Testing
- filgrastim, pegfilgrastim, carboplatin
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sarcoma
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00742924
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients
Improvement of event free survival of high-risk neuroblastoma patients by introduction of two additional topotecan containing chemotherapy cycles into the multimodal standard treatment (induction chemotherapy, myeloablative…
- Trial name
- NB2004-HR (NCT03042429)
- Testing
- Cycles N8, N5 and N6, Cycles N5 and N6
- Where
- Germany
- Volunteers
- 360 people
- Sponsor
- University of Cologne
DLBCL - Diffuse Large B Cell Lymphoma
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R …
- Trial name
- NCT07389356
- Testing
- Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Unresectable Sinonasal Tumors
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Sinonasal tumors are rare diseases, as they account for the 0.2 % - 0.8 % of all tumors. For patients with inoperable tumors, the prognosis is poor and the current therapy is a combined-modality treatment that is both more…
- Trial name
- NCT02099188
- Testing
- Cisplatin, Docetaxel, 5-fluorouracil
- Where
- 5 sites in Italy
- Volunteers
- 27 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Rhabdomyosarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Trial name
- FaR-RMS (NCT04625907)
- Testing
- Irinotecan, Actinomycin D, Doxorubicin
- Where
- 128 sites in Australia, Austria and 18 more
- Volunteers
- 1,672 people
- Sponsor
- University of Birmingham
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for…
- Trial name
- NCT00199056
- Testing
- Dexamethasone / Prednisolone, Cyclophosphamide, Methotrexate
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- Goethe University
Hodgkin's Lymphoma
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is determine if 2 cycles of SGN-35 can be used instead of ICE prior to autologous stem cell transplant (ASCT) for relapsed and refractory HL.
- Trial name
- NCT01508312
- Testing
- brentuximab vedotin (SGN-35)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell…
- Trial name
- NCT00842595
- Testing
- rituximab, vinorelbine, ifosfamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- French Innovative Leukemia Organisation